Emergent Health Corp. (Pink Sheets: EMGN) is pleased to announce that it has appointed Investor Development Group, LLC as its investor relations agent for North America.
Investor Development Group will help in communicating to the investor community, prospective investors, shareholders and members of the professional investment community, assist with the creation of written materials, provide counsel to the company with respect to investor relations initiatives, and work to achieve a greater level of corporate transparency and public awareness.
Significant and ongoing developments within EMGN have made the implementation of a comprehensive communications plan essential for the company. "Our number one priority now, as it always has been, is simple - to maximize shareholder value," says Robert Adams, IDG President. "The experience and range of investor relations solutions provided by IDG will go a long way to help EMGN achieve that goal."
"It is my privilege to work with EMGN and the rest of the team. Their leadership team and products presents an exciting opportunity for us. We look forward to communicating their message and assisting in shareholder outreach," added Robert Adams.
About Investor Development Group, LLC:
Investor Development Group, LLC is a traditional boutique investor relations firm based in Houston, TX. Their expertise is in the representation of emerging public companies to the individual and professional investment communities. IDG assists with the creation of written corporate materials, composes media submissions, helps expose its clients to the investment community, serves as corporate liaison to shareholders and inquirers, and offers strategic assistance and consulting in a number of practice areas. Some of our more recent clients include Dixie Lee International "DLII", Cardiovascular Sciences "CVSC".
About Emergent Health
Emergent engages in the discovery, development and marketing of products designed to better mankind. Emergent believes it is positioning itself as a leader in the field of Regenerative Medicine defined by the National Institute of Health using nutritionally designed products. Intended products are to be marketed under third party label exemptions. Emergent is focusing current efforts on marketing licensed patent pending natural stem cell propagating agents capable of enhancing each individual's ability to propagate their own adult stem cells from their bone marrow. Emergent is also licensed under a patent pending application to market a dual acting all natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets. Research and Development is exploring other areas such as Secretogues that can naturally enhance a person's own Growth Hormone production and similar all natural bioactive formulations to enhance human performance safely, ethically, legally and utilizing known body mechanisms without the use of drugs. Emergent does not claim any of its products diagnose, treat, cure or prevent any disease. Emergent was founded in 2006 and headquartered in Myrtle Beach, SC. http://www.emergenthealth.com http://www.vita-stim.com
This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.